Oppenheimer Reiterates CASI Pharmaceuticals (CASI) at Outperform, "CASI is an Underappreciated Story Among Small-cap Biotechs"
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $6.00 price target on CASI Pharmaceuticals (NASDAQ: CASI), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
